期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨肿瘤的遗传基因学改变 被引量：4

The genetic changes of bone neoplasms
下载PDF
导出
摘要 在骨肿瘤发生、发展过程中牵涉到许多遗传基因学的改变。随着分子生物学技术的发展 ,对这些遗传基因学改变进行敏感而特异的检测 ,有助于对骨肿瘤进行分子诊断。 Many genetic changes are involved in the genesis and progression of bone neoplasms. With the development of molecular biology techniques, the analysis of the changes can be used as a highly specific diagnostic tools and important prognostic indicators and provide key information for designing novel therapeutic modalities.
作者 李志刚
机构地区 南京军区南京总医院病理科
出处 《医学研究生学报》 CAS 2003年第2期138-141,共4页 Journal of Medical Postgraduates
关键词 骨肿瘤 分子标志 预后 Bone neoplasms Molecular mark Prognosis
分类号 R738.1 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Ligon AH, Potocki L, Shaffer LG, et al. Gene for multiple exostoses(EXT2) maps to 11(p11.2-12) and is deleted in patients with a contiguous gene deletion[J]. AM J Med Genet, 1998, 75(5): 538-540.
  • 2Porter DE, Simpson AHRW. The neoplastic pathogenesis of solitary and multiple osteochondromas[J]. J Pathol, 1999, 188(2):119-125.
  • 3Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma[J]. Int J Cancer, 1999, 84(2): 114-121.
  • 4Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the Rb gene is a poor prognostic factor in patients with osteosarcoma[J]. J Clin Oncol, 1996, 14(2): 467-472.
  • 5Patino Garcia A, Sierrasesumaga, Ariznabarreta L. Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children[J]. An Esp Pediatr, 1997, 47(5): 478-482.
  • 6Horstmann MA, Posl M, Scholz RB, et al. Frequent reduction or loss of DCC gene expression in human osteosarcoma[J]. Br J Cancer, 1997, 75(9): 1309-1317.
  • 7Kruzelock RP, Murphy EC, Strong LC, et al. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis[J]. Cancer Res, 1997, 57(1): 106-109.
  • 8Gamberi G, Ragazzini P, Benassi MS, et al. Analysis of 12q13-15 genes in parosteal osteosarcoma[J]. Clin Orthop, 2000, (377): 195-204.
  • 9Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma[J]. Cancer, 1996, 77(1): 71-78.
  • 10Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma[J]. Oncology, 2001, 60(4): 361-366.

同被引文献37

  • 1阴瑞.术后疼痛护理评估和控制对策[J].实用医技杂志,2006,13(12):2153-2154. 被引量：32
  • 2程凯,李雪萍,于俊龙.全膝关节置换术后的康复治疗要点与相关研究[J].中国康复理论与实践,2006,12(10):875-876. 被引量：38
  • 3Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presur- gical chemotherapy compared with immediate surgery and ad- juvant chemotherapy for nonmetastatic osteosarcoma: Pediat- ric Oncology Group Study POG-8651[J]. J Clin Oncol, 2003, 21(8) : 1574-1580.
  • 4Bielaek SS, Kempf-Bielack 13, Delling G, et al. Prognostic fac- tors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002,20 (3) :776-790.
  • 5Link MP, Goorin AM, Miser AW, et al. The effect of adju- vant chemotherapy on relapse-free survival in patients with os- teosarcoma of the extremity[J]. N Engl J Med, 1986, 314 (25): 1600-1606.
  • 6Enneking WF, Dunham W , Gebhardt MC, et al. A system for the functional evaluation of reconstructive pracedures after surgical treatment of tumors of the musculoskeletal system [J]. Clin Orthop Relat Res, 1993,286(1) : 241-246.
  • 7Coussens L, Yang-feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene[J]. Scinece, 1985,230(12):1132-1139.
  • 8Bacci G, Ferrari S, Bertoni F et al, Long-term outcome for patients with nonmetastatic osteosarcoma of the exthemity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/ osteosarcoma-2 protocol: an update report[J]. J Clin Oncol, 2000,18(24):4016-4027.
  • 9Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-p185HER2 monoclonal antibody in women who have HER2-overexpression metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J]. J Clin Oncol, 1999,17(9):2639-2648.
  • 10Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792.

引证文献4

二级引证文献28

医学研究生学报
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部